Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger
will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.

Carolinas HealthCare System

Dr. Tcheremissine, director of research, department of psychiatry and behavioral sciences at Carolinas HealthCare System

Oleg V. Tcheremissine, MD, wants your Alzheimer’s patients.

Dr. Tcheremissine, director of research, department of psychiatry and behavioral sciences at Carolinas HealthCare System Behavioral Health-Charlotte, is one of those scientists who works tirelessly to help patients with Alzheimer's.

“Tremendous progress has been made in the past decade in broadening our understanding of the underlying biology, physiology, and neurochemistry, as well as brain function and brain circuitry surrounding Alzheimer's, said Dr. Tcheremissine.

But he wants more than just broadening our understanding. He wants to find a cure.

To that end, Dr. Tcheremissine has participated in many clinical trials aimed at Alzheimer’s patients. The latest, now open to patients, wants to change the disease’s trajectory and improve quality of life. These trials could prove to be critical. More than 5 million Americans have Alzheimer's and by 2050, it is estimated that 14 million Americans could be living with the disease unless scientists develop new ways to prevent or cure it.

“These advancements in neuroscience established a solid foundation for the development of new generations of therapeutic targets and new molecular entities,” Dr. Tcheremissine said. “Therefore, our research is absolutely critical, and we believe this trial will help in the treatment and management of this disease."

The multicenter, international study about Alzheimer's disease (AD) is now open to patients at Carolinas HealthCare System. To potentially qualify for the study, Dr. Tcheremissin is looking for male and female patients who are between 55 and 85 with mild to moderate dementia due to Alzheimer's disease. These patients are currently or have previously been treated with an acetylcholinesterase inhibitor medication (donepezil, galantamine or rivastigmine).

Carolinas HealthCare System is uniquely positioned for this study because of the strong multidisciplinary program in place and the large patient population served in the Charlotte region. In addition, the System is home to some of the world’s most qualified pool of physician-investigators.

If you have patients you think may qualify for the clinical trial, please call (704) 446-7511 for more information.